Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 5/20 | 0.54 |
| ▸ | CDK2 | P24941 | 5/20 | 0.54 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.54 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.43 |
| ▸ | KCNN3 | Q9UGI6 | 1/20 | 0.40 |
| ▸ | AURKA | O14965 | 1/20 | 0.40 |
| ▸ | APP | P05067 | 1/20 | 0.39 |
| ▸ | GRM5 | P41594 | 1/20 | 0.39 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.38 |
| ▸ | SYK | P43405 | 1/20 | 0.37 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.36 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7767535 | 0.95 | CDK2 (0.50) | CDK4CDK2CCNE1GRM4KCNN3 | |
| SCHEMBL5388892 | 0.85 | MAPK14 (0.46) | CDK4CDK2CCNE1MAPK10SYK | |
| SCHEMBL658219 | 0.85 | CDK4 (0.47) | CDK4CDK2CCNE1AURKASYK | |
| SCHEMBL4433403 | 0.82 | MEN1 (0.43) | CDK4CDK2CCNE1APPPIK3CG | |
| SCHEMBL5397901 | 0.80 | CDK2 (0.47) | CDK4CDK2CCNE1AURKAAPP | |
| SCHEMBL5402771 | 0.79 | RAB9A (0.44) | CDK4CDK2CCNE1SYKPIK3CG | |
| SCHEMBL18386919 | 0.79 | APP (0.40) | CDK4CDK2CCNE1APPMAPK10 | |
| SCHEMBL4433335 | 0.79 | RECQL (0.41) | CDK4CDK2CCNE1AURKAGRM5 | |
| SCHEMBL14611819 | 0.79 | CDK4 (0.51) | CDK4CDK2CCNE1GRM4KCNN3 | |
| SCHEMBL12813310 | 0.78 | AURKA (0.61) | CDK4CDK2AURKAMAPK10SYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100445270-C | Pyrimidine compounds | ASTRAZENECA AB (SE) | 2008-12-24 | — | — | CN | disclosed |
| EP-1272477-B1 | PYRIMIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2007-05-09 | — | — | EP | disclosed |
| US-7176212-B2 | 2,4-diamino pyrimidine compounds having anti-cell proliferative activity | ASTRAZENECA AB (SE) | 2007-02-13 | — | — | US | disclosed |
| US-7176212-B2 | 2,4-diamino pyrimidine compounds having anti-cell proliferative activity | ASTRAZENECA AB (SE) | 2007-02-13 | — | — | US | disclosed |
| US-7176212-B2 | 2,4-diamino pyrimidine compounds having anti-cell proliferative activity | ASTRAZENECA AB (SE) | 2007-02-13 | — | — | US | disclosed |
| US-7153964-B2 | Pyrimidine compounds | ASTRAZENECA AB (SE) | 2006-12-26 | — | — | US | disclosed |
| EP-1107957-B1 | PYRIMIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2006-10-18 | — | — | EP | disclosed |
| US-20050090493-A1 | 2,4-Diamino pyrimidine compounds having anti-cell proliferative activity | ASTRAZENECA AB | 2005-04-28 | — | — | US | disclosed |
| US-20030149064-A1 | Pyrimidine compounds | ASTRAZENECA AB (SE) | 2003-08-07 | — | — | US | disclosed |
| CN-1406231-A | Pyrimidine compounds | ASTRAZENECA AB (SE) | 2003-03-26 | — | — | CN | disclosed |
| EP-1272477-A1 | PYRIMIDINE COMPOUNDS | AstraZeneca AB (SE) | 2003-01-08 | — | — | EP | disclosed |
| WO-2001064654-A1 | PYRIMIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2001-09-07 | — | — | WO | disclosed |
| EP-1107957-A1 | PYRIMIDINE COMPOUNDS | AstraZeneca AB (SE) | 2001-06-20 | — | — | EP | disclosed |
| WO-2000012485-A1 | PYRIMIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2000-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050090493-A1 | 2,4-Diamino pyrimidine compounds having anti-cell proliferative activity | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, H1-3, H1-0 | CDK4 113/4885CDK2 74/4885CCNE1 22/4885 |
| US-20030149064-A1 | Pyrimidine compounds | CDK2, CCNI, CCNY | CDK4 11/4885CDK2 1/4885CCNE1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.